Nanexa Stock Soars 114% After Securing $1.3 Billion Novo Nordisk Licensing Deal

Nanexa (NEXA) surged 114% in after‑hours trading following the announcement that Novo Nordisk (NVO) will pay $1.3 billion for a license to its proprietary drug candidate. The deal, which will provide Nanexa with a substantial cash infusion and a strategic partnership, has propelled the company’s shares to new highs. Analysts note that the transaction could accelerate Nanexa’s product pipeline and enhance its valuation.